AzTrials
AzTrials

Atrial FibrillationSWISS-AFNCT02105844

Swiss Atrial Fibrillation Cohort Study

An observational study of Atrial Fibrillation, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged >65 years will be included and followed on a yearly basis. Read more about this study

Who is it for?
Ages 45 years and older
Conditions the study is for
Atrial Fibrillation
How many people
2,415 participants
Where
1 siteSwitzerland
Study dates
Mar 2014to Mar 2030
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Consecutive patients with atrial fibrillation

Who may be able to join

  • atrial fibrillation documented within the last 24 months
  • age >=45 years

Who cannot join

  • acute illness
  • inability to provide informed consent
  • Only short episodes of reversible forms of atrial fibrillation

Trial locations and contacts

1 site in 1 country.

Switzerland1 site

  • University Hospital

    Basel, Canton of Basel-City, 4031

Other trials in Switzerland

About this study

Official title: Swiss Atrial Fibrillation Cohort Study - SWISS AF

Swiss-AF is a prospective observational, multicentric cohort study in Switzerland. Overall, 2600 patients with documented atrial fibrillation aged >65 years will be included and followed on a yearly basis.

Yearly clinical examinations include a detailed questionnaire on personal characteristics, a resting electrocardiogram, neurocognitive function tests and questionnaires on disability and quality of life. Blood sampling and brain magnetic resonance imaging are scheduled at baseline and after 2 years of follow-up.

The main study aims of this long term prospective study are to increase our knowledge on structural brain damage and its changes over time in patients with atrial fibrillation, to gain additional insights on the incidence and underlying mechanisms of cognitive decline in patients with atrial fibrillation and to evaluate the interrelationships of structural and functional brain damage in this population.

Keywords
atrial fibrillation, dementia, cognitive dysfunction, stroke, Magnetic resonance imaging
Medical subject headings
Atrial Fibrillation, Dementia, Cognitive Dysfunction, Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02105844
Study groupRoleWhat they receive
Atrial FibrillationCohort Study on patients with atrial fibrillation in Switzerland

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stroke or systemic embolism

    Measured: 2018 (after an average of 2.5 years of follow-up)

Secondary outcomes (1)

  1. Hospitalization for heart failure

    Measured: 2018 (after an average of 2.5 years of follow-up)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Apr 2014 (estimated)
  2. Study startMar 2014
  3. Primary completionMar 2030 (estimated)
  4. Study completionMar 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,415 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02105844
Sponsor's protocol ID
SWISS-AF
Acronym
SWISS-AF
Status last verified
Jul 2025
First submitted
28 Mar 2014
Last updated
9 Jul 2025
Results posted
No
Data monitoring committee
No

Publications

  • Krisai P, Mutti M, Aeschbacher S, Coslovsky M, Reichlin T, Rodondi N, Ammann P, Moschovitis G, Rigamonti E, Conte G, Haller ML, Stoecklin A, Bonati LH, Osswald S, Conen D, Mahfoud F, Kuhne M. Impact of differences in kidney function estimation by creatinine compared to cystatin C on clinical outcomes in patients with atrial fibrillation. Eur Heart J Open. 2026 Sep 22;6(5):oeag145. doi: 10.1093/ehjopen/oeag145. eCollection 2026 Sep.

    PubMed 42846172

  • Hennings E, Aeschbacher S, Neuschwander P, Coslovsky M, Istampoulouoglou I, Leuppi-Taegtmeyer A, Paladini RE, Strobel L, Reichlin T, Rodondi N, Beer JH, Conte G, Auricchio A, Moschovitis G, Di Valentino M, Adam L, De Perna ML, Bonati LH, Mahfoud F, Krisai P, Zuern CS, Conen D, Sticherling C, Osswald S, Kuhne M; Swiss-AF Investigators17. Drug-drug interactions of NOACs with comedication: Prevalence and implications for adverse events in patients with atrial fibrillation. Heart Rhythm O2. 2026 Jun 18;7(9):1680-1690. doi: 10.1016/j.hroo.2026.06.007. eCollection 2026 Sep.

    PubMed 42774679

  • Koechlin M, Paladini RE, Aeschbacher S, Zuern CS, Strebel I, Coslovsky M, Liskij M, Kerler R, Krisai P, Bonati LH, Conen D, Mahfoud F, Osswald S, Kuhne M, Kaufmann BA. Progression of mitral and tricuspid regurgitation in patients with and without atrial fibrillation. Front Cardiovasc Med. 2026 Jul 1;13:1878401. doi: 10.3389/fcvm.2026.1878401. eCollection 2026.

    PubMed 42459191

  • Bhend K, Paladini R, Aeschbacher S, Hennings E, Coslovsky M, Krisai P, Rodondi N, Beer J, Auricchio A, Moschovitis G, Storrer N, Chocano-Bedoya PO, Rigamonti E, Sinnecker T, Conen D, Osswald S, Bonati L, Kuhne M. Brain lesions and cognitive decline in patients with atrial fibrillation: a prospective multicentre cohort study. Swiss Med Wkly. 2026 Jan 9;156:4059. doi: 10.57187/s.4059.

    PubMed 41962126

  • Kupper BC, Reiner MF, Werlen L, Aeschbacher S, Lee P, Allemann MS, Moschovitis G, Luscher T, Camici GG, Rodondi N, Adam L, Meyre PB, Bonati LH, Sinnecker T, Kuhne M, Osswald S, Conen D, Beer JH; Swiss-AF Investigators. Plasma beta-Thromboglobulin Is Inversely Associated With Cerebral Microbleeds in Atrial Fibrillation. Stroke. 2025 Dec;56(12):3414-3423. doi: 10.1161/STROKEAHA.124.049972. Epub 2025 Sep 17.

    PubMed 40959897

  • Iten V, Herber E, Coslovsky M, Hennings E, Paladini RE, Reichlin T, Rodondi N, Muller AS, Stauber A, Beer JH, Brenner R, Conte G, Kobza R, Di Valentino M, Bedoya PC, Moradi F, Sinnecker T, Bonati LH, Kuhne M, Osswald S, Conen D, Aeschbacher S, Zuern CS; Swiss-AF and Beat-AF Investigators. Coffee consumption and adverse cardiovascular events in patients with atrial fibrillation. BMC Med. 2024 Dec 18;22(1):593. doi: 10.1186/s12916-024-03817-x.

    PubMed 39696255

  • Barbagallo M, Springer A, Vanetta C, Allemann M, Lee P, Saeedi S, Aeschbacher S, Luciani M, Bonati LH, Moschovitis G, Scheu V, Rutishauser J, Kobza R, Di Valentino M, Meyre PB, Rodondi N, Conen D, Kuhne M, Osswald S, Beer JH; Swiss-AF investigators. Coffee Consumption Correlates With Better Cognitive Performance in Patients With a High Incidence for Stroke. J Am Heart Assoc. 2025 Jan 7;14(1):e034365. doi: 10.1161/JAHA.124.034365. Epub 2024 Dec 14.

    PubMed 39673298

  • Carmine D, Aeschbacher S, Coslovsky M, Hennings E, Paladini RE, Peter R, Burger M, Reichlin T, Rodondi N, Muller AS, Ammann P, Conte G, Auricchio A, Moschovitis G, Bardoczi JB, Stauber A, De Perna ML, Zuern CS, Sinnecker T, Badertscher P, Sticherling C, Bonati LH, Conen D, Krisai P, Osswald S, Kuhne M. Blood pressure, brain lesions and cognitive decline in patients with atrial fibrillation. Front Cardiovasc Med. 2024 Sep 3;11:1449506. doi: 10.3389/fcvm.2024.1449506. eCollection 2024.

    PubMed 39314770

  • Reiner MF, Bertschi DA, Werlen L, Wiencierz A, Aeschbacher S, Lee P, Rodondi N, Moutzouri E, Bonati L, Reichlin T, Moschovitis G, Rutishauser J, Kuhne M, Osswald S, Conen D, Beer JH. Omega-3 Fatty Acids and Markers of Thrombosis in Patients with Atrial Fibrillation. Nutrients. 2024 Jan 5;16(2):178. doi: 10.3390/nu16020178.

    PubMed 38257071

  • Stauber A, Muller A, Rommers N, Aeschbacher S, Rodondi N, Bonati LH, Beer JH, Jeger RV, Kurz DJ, Liedtke C, Ammann P, Di Valentino M, Chocano P, Kobza R, Kuhne M, Conen D, Osswald S, Bernheim AM. Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF). Swiss Med Wkly. 2023 Aug 23;153:40109. doi: 10.57187/smw.2023.40109.

    PubMed 37609948

  • Hennings E, Blum S, Aeschbacher S, Coslovsky M, Knecht S, Eken C, Lischer M, Paladini RE, Krisai P, Reichlin T, Rodondi N, Beer JH, Ammann P, Conte G, De Perna ML, Kobza R, Blum MR, Bossard M, Kastner P, Ziegler A, Muller C, Bonati LH, Pfister O, Zuern CS, Conen D, Kuhne M, Osswald S; Swiss-AF Investigators. Bone Morphogenetic Protein 10-A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation. J Am Heart Assoc. 2023 Mar 21;12(6):e028255. doi: 10.1161/JAHA.122.028255. Epub 2023 Mar 16.

    PubMed 36926939

  • Luciani M, Muller D, Vanetta C, Diteepeng T, von Eckardstein A, Aeschbacher S, Rodondi N, Moschovitis G, Reichlin T, Sinnecker T, Wuerfel J, Bonati LH, Saeedi Saravi SS, Chocano-Bedoya P, Coslovsky M, Camici GG, Luscher TF, Kuehne M, Osswald S, Conen D, Beer JH; SWISS-AF Investigators. Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation. Heart. 2023 Feb 14;109(5):396-404. doi: 10.1136/heartjnl-2022-321300.

    PubMed 36593094

  • Zwimpfer L, Aeschbacher S, Krisai P, Coslovsky M, Springer A, Paladini RE, Girod M, Hufschmid J, Knecht S, Badertscher P, Beer JH, Bonati LH, Zuern CS, Roten L, Reichlin T, Sticherling C, Conen D, Osswald S, Kuhne M. Neurocognitive function in patients with atrial fibrillation undergoing pulmonary vein isolation. Front Cardiovasc Med. 2022 Nov 25;9:1000799. doi: 10.3389/fcvm.2022.1000799. eCollection 2022.

    PubMed 36505379

  • Girod M, Coslovsky M, Aeschbacher S, Sticherling C, Reichlin T, Roten L, Rodondi N, Ammann P, Auricchio A, Moschovitis G, Kobza R, Badertscher P, Knecht S, Krisai P, Marugg A, Aebersold H, Hennings E, Serra-Burriel M, Schwenkglenks M, Zuern CS, Bonati LH, Conen D, Osswald S, Kuhne M. Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. Clin Res Cardiol. 2022 Sep;111(9):1048-1056. doi: 10.1007/s00392-022-02015-0. Epub 2022 Apr 11.

    PubMed 35403852

  • Rivolta MW, Mainardi LT, Laureanti R, Sassi R, Kuhne M, Rodondi N, Conte G, Moschovitis G, Schlageter V, Aeschbacher S, Conen D, Reichlin T, Roten L, Osswald S, Zuern CS, Auricchio A, Corino VDA. Association between ventricular repolarization parameters and cardiovascular death in patients of the SWISS-AF cohort. Int J Cardiol. 2022 Jun 1;356:53-59. doi: 10.1016/j.ijcard.2022.03.009. Epub 2022 Mar 9.

    PubMed 35278571

Questions about this trial

What is this clinical trial studying?

An observational study of Atrial Fibrillation, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stroke or systemic embolism (time frame: 2018 (after an average of 2.5 years of follow-up)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02105844, which also lists 26 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025; AzTrials last refreshed its copy on 3 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in